Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
3.940
-0.130 (-3.19%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Kalaris Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The meeting focused on a reverse stock split proposal and a potential adjournment if more proxies were needed. Voting was conducted with a quorum present, and results will be published after certification. No questions were raised by stakeholders.
Fiscal Year 2024
-
A merger will create a well-funded company focused on advancing TH103, a next-generation anti-VEGF therapy for retinal diseases. The deal is expected to close in Q1 2025, with a strong management team and sufficient cash to fund operations through 2026.